Singapore's first commercial developer of molecular diagnostic assays opens operations
Dx Assays Pte Ltd will commence operations on 8 September, as Singapore’s first commercial developer of molecular diagnostic assays, according to the compay. The company will develop and validate molecular diagnostic assays for biotech and pharmaceutical companies. This shall help Dx Assays’ clients in their drug discovery and development efforts, as well as assist in the tailored approach of personalized medicine.
Dx Assays is a joint venture between Qiagen and Bio*One Capital, the dedicated biomedical science investment company of EDB Investments.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has Received Orphan Drug Designation From the FDA
GENFIT: Promising GFT505 results in Phase II
